Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia: early-phase trial registry
51 of 274 indexed Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #35 of 28,707 conditions by registered trial count.
274 US clinical trials · 51 currently recruiting · #35 of 28,707 conditions by registered trial count
Leukemia: 274 US clinical trials tracked, 51 recruiting.
Leukemia is the subject of 274 registered US clinical trials on ClinicalTrials.gov, 51 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 193 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 37 of these trials.
Enrollment posture brief
Registry condition leukemia
OPEN 51 | RECR 19% | LATE 19 | EARLY 193 | RANK #35 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Rheumatoid Arthritis (19% recruiting · 199 trials)
Leukemia lists 51 open slots (19% of 274 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia is recruiting below its size-band peers.
51 of 274 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 37 of 274 trials (13.5%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 234 trials that report a genuine target (sentinel values excluded). 170 of those (72.6%) plan for fewer than 100 participants.
-
Leukemia research is mostly interventional.
243 interventional and 31 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
274 total, page 3 of 6
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Alliance for Clinical Trials in Oncology
NCT00417040
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT01289457
Illness Management and Parental Adjustment to Cancer Treatment
Children's Hospital Medical Center, Cincinnati
NCT02505165
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Mayo Clinic
NCT00436618
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT00003341
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT00597714
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Children's Oncology Group
NCT00003593
Validating Pain Scales in Children and Young Adults
National Cancer Institute (NCI)
NCT01639950
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
NCT00369564
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00469144
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT00002756
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT02269280
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00580034
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT00002704
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
SWOG Cancer Research Network
NCT00016419
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
NCT00607997
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
SWOG Cancer Research Network
NCT00492856
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
NCT00039130
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
NCT00003248
Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone
M.D. Anderson Cancer Center
NCT05049785
Topotecan in Treating Patients With Myelodysplastic Syndrome
Alliance for Clinical Trials in Oncology
NCT00003675
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Memorial Sloan Kettering Cancer Center
NCT00582933
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00278161
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
Roswell Park Cancer Institute
NCT00003662
African American Cancer Clinical Trial Decisions: Testing Tailored Messages
Virginia Commonwealth University
NCT02356549
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Memorial Sloan Kettering Cancer Center
NCT01682226
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Children's Oncology Group
NCT00005977
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
NCT00053196
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
NCT00109837
Improving Patient Education for Lymphoma and Leukemia Inpatients
Emory University
NCT02642510
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT00048737
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00179868
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
SWOG Cancer Research Network
NCT00066794
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT00816595
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
NCT01027000
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
NCT01794702
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
NCT00038844
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT00093483
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT02305979
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
NCT00857389
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
Children's Oncology Group
NCT00003671
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
University of Michigan Rogel Cancer Center
NCT02409121
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme
NCT00086125
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Pfizer
NCT00003673
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00002553
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Memorial Sloan Kettering Cancer Center
NCT00546377
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
SWOG Cancer Research Network
NCT00002665
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 95 |
| Phase 3 | 18 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia page
274 registered trials, 51 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 51 Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia condition card totals 274 registered trials; most-linked intervention cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.